Panacea Biotec Board Approves FY26 Results, Appoints New Director
Panacea Biotec reported standalone net loss of ₹2,988 Lakh for FY26 and consolidated net loss of ₹1,523 Lakh. The company will not pay a dividend for FY26 due to losses. Mr. Rajinder Singh Manku was appointed as an additional non-executive independent director from July 1, 2026. DengiAll® vaccine trials are complete.
The appointment of a new director is a governance change, while the financial loss and dividend decision have a direct impact on financial stakeholders. The progress on the dengue vaccine is a positive long-term outlook but does not immediately offset the current financial results.
The company reported a net loss for the quarter and financial year, and decided to pass over the dividend, indicating a negative financial performance.
Panacea Biotec Limited announced on May 30, 2026, that its Board of Directors has approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The company reported a net loss after tax of ₹18 Lakh for the quarter ended March 31, 2026, and a net loss after tax of ₹2,988 Lakh for the financial year ended March 31, 2026, on a standalone basis. Consolidated, the net loss after tax was ₹100 Lakh for the quarter and ₹1,523 Lakh for the financial year. The Board also decided to pass over the dividend for the financial year 2025-26 due to losses incurred. Additionally, Mr. Rajinder Singh Manku has been appointed as a non-executive independent director for a term of 5 consecutive years, effective July 01, 2026, subject to shareholder approval. The Board meeting commenced at 4:30 PM and concluded at 8:10 PM.
The company's financial results were reviewed by the Audit Committee on May 29, 2026, and subsequently approved by the Board. The auditors' report on these results carries an unmodified opinion. Panacea Biotec Limited has also completed the enrollment of study participants for its DengiAll® Phase-III clinical trial, which is expected to result in India's first indigenous single-shot dengue vaccine by 2027, pending successful trials and regulatory approvals. The company's financial statements indicate conditions that may cast doubt on its ability to continue as a going concern on a standalone basis, but the management believes the going concern basis is appropriate due to strengthening working capital and ongoing business development efforts.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.